2019
Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort
Sethi T, Kovach A, Mason E, Chen H, Moyo T, Oluwole O, Morgan D, Reddy N. Combination of Nivolumab, Lenalidomide and Rituximab in Relapsed/Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma: Results from a Dose-Escalation Cohort. Blood 2019, 134: 4100. DOI: 10.1182/blood-2019-129634.Peer-Reviewed Original ResearchOverall response rateProgression-free survivalDiffuse large B-cell lymphomaLarge B-cell lymphomaCombination of nivolumabDose-escalation cohortsNon-GCB DLBCLPrimary refractory diseaseB-cell lymphomaOverall survivalDay 1Prior linesRefractory diseaseCell lymphomaNon-germinal center diffuse large B-cell lymphomaSingle-arm open-label studyResponse rateAutologous stem cell transplantCommon grade 3/4 toxicitiesMedian progression-free survivalNon-germinal centre DLBCLAnti-PD-1 antibodyDiffuse large B-cell lymphoma patientsLarge B-cell lymphoma patientsCAR T-cell therapy
2015
Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma
Chen J, Lenihan D, Phillips S, Jagasia M, Goodman S, Kassim A, Lacy S, McDonagh K, Moslehi J, Sethi T, Slosky D, Ukaegbu O, Cornell R. Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma. Blood 2015, 126: 5363. DOI: 10.1182/blood.v126.23.5363.5363.Peer-Reviewed Original ResearchCardiac adverse eventsIndependent risk factorCardiac eventsCumulative incidenceRisk factorsMultiple myelomaPrior historyAdverse eventsAntithrombotic therapyPI therapyMedian durationPrior linesMore patientsMale genderAtherosclerotic cardiovascular disease riskC groupCardiac Toxicity AssociatedMedian prior linesLipid-lowering medicationsB groupCardiovascular disease riskStem cell transplantationCourse of treatmentProteasome inhibitor bortezomibIncidence of PI